Filippo de Braud
University of Milan
607 Papers
1.8K Citations
Filippo de Braud is an academic researcher from University of Milan. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 62, co-authored 511 publications. Previous affiliations of Filippo de Braud include European Institute of Oncology & Autonomous University of Barcelona.
Chat about Author
Papers
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers
Riccardo Lobefaro,Giuseppe Viscardi,Raimondo Di Liello,Giacomo Massa,Maria Lucia Iacovino,Francesca Sparano,Carminia Maria Della Corte,Roberto Ferrara,Diego Signorelli,Claudia Proto,A. Prelaj,Giulia Galli,Alessandro De Toma,Marta Brambilla,Monica Ganzinelli,Benedetta Trevisan,Fortunato Ciardiello,Filippo de Braud,Floriana Morgillo,Marina Chiara Garassino,Giuseppe Lo Russo +20 more
TL;DR: Reduced efficacy of immunotherapy in patients with poor PS is confirmed even though a good safety, despite PS remains the most powerful independent prognostic factor for NSCLC, LDH levels and steroids exposure could support the decision making in PS2 patients.
Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b.
Elisabetta Vergani,Lorenza Di Guardo,Matteo Dugo,Sara Rigoletto,Gabrina Tragni,Roberta Ruggeri,Federica Perrone,Elena Tamborini,Annunziata Gloghini,Flavio Arienti,Barbara Vergani,Paola Deho,Loris De Cecco,Viviana Vallacchi,Paola Frati,Eriomina Shahaj,Antonello Villa,Mario Santinami,Filippo de Braud,Licia Rivoltini,Monica Rodolfo +20 more
TL;DR: Inhibition of CCL2 and of the selected miRNAs restored both the cell apoptosis and the drug efficacy in resistant melanoma cells, which are potential prognostic factors and attractive targets for counteracting treatment resistance in metastatic melanoma.
Role of cMET in the development and progression of colorectal cancer.
Juan Carlos Samamé Pérez-Vargas,Pamela Biondani,Claudia Maggi,Manuela Gariboldi,Annunziata Gloghini,Alessandro Inno,Chiara C. Volpi,Ambra Vittoria Gualeni,Maria Di Bartolomeo,Filippo de Braud,Alessandra Castano,Ilaria Bossi,Filippo Pietrantonio +12 more
TL;DR: HGF and MET are new promising targets to understand the pathogenesis of CRC and for the development of new, targeted therapies.
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups
Michele Simbolo,Matteo Fassan,Andrea Ruzzenente,Andrea Mafficini,Laura D. Wood,Vincenzo Corbo,Davide Melisi,Giuseppe Malleo,Caterina Vicentini,Giorgio Malpeli,Davide Antonello,Nicola Sperandio,Paola Capelli,Anna Tomezzoli,Calogero Iacono,Rita T. Lawlor,Claudio Bassi,Ralph H. Hruban,Alfredo Guglielmi,Giampaolo Tortora,Filippo de Braud,Aldo Scarpa +21 more
TL;DR: This study identified molecular subgroups of cholangiocarcinomas that can be explored for specific drug targeting in clinical trials and identified tumour stage and TP53 mutations as independent predictors of survival.
BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): Updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advBC).
Josep Tabernero,Jason J. Luke,Anthony M. Joshua,Andrea Varga,Victor Moreno,Jayesh Desai,Ben Markman,Carlos Gomez-Roca,Filippo de Braud,Sandip Pravin Patel,Matteo S. Carlino,Lillian L. Siu,Giuseppe Curigliano,Zhaohui Liu,Yuko Ishii,Penny Phillips,Megan Wind-Rotolo,P. Basciano,Alex Azrilevich,Karen A. Gelmon +19 more
TL;DR: Nivo (antiPD-1) has shown durable responses and manageable safety and ORR, 19.6%; grade 3‒4 treatment-related AEs [TRAEs], 18%) in advBC (Sharma et al. 2017).